Genmab and AbbVie report 51% lower risk of progression with epcoritamab plus R‑CHOP in frontline DLBCL
Genmab and AbbVie announced topline data from the Phase 3 EPCORE DLBCL‑2 study showing that adding epcoritamab to standard R‑CHOP cuts the risk of disease progression or death by 51% in newly diagnosed diffuse large B‑cell lymphoma patients with an International Prognostic Index of 2‑5. The hazard ratio was reported as 0.49 with a p‑value below 0.0001. Both companies said they will discuss the results with global regulators and plan to present the data at a future medical meeting.
Why it matters
The company says the hazard‑ratio reduction could position the combination as a new frontline option for high‑risk DLBCL, potentially expanding the market for epcoritamab. Analysts note the strong efficacy signal may boost investor sentiment toward both firms.
Key facts
- 1The trial showed a 51% reduction in the risk of progression or death (HR 0.49). marketscreener.com
- 2The p‑value for the primary endpoint was reported as less than 0.0001. prnewswire.com
- 3Patients enrolled had an International Prognostic Index score of 2 to 5. marketscreener.com
- 4The study randomized participants in a 2:1 ratio to epcoritamab + R‑CHOP versus R‑CHOP alone. marketscreener.com
- 5The trial began on February 8 2023 and is still ongoing. marketscreener.com
- 6Epcoritamab is currently approved for other lymphoma indications but not for this combination. prnewswire.com
Summary written by AlphAI from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.